Lexicon Genetics der nächste Starter ????? - 500 Beiträge pro Seite

[js200]

Lexicon Genetics Appoints Alan S. Nies, M.D. Chairman of the Medical Advisory Board
via COMTEX

March 25, 2003

THE WOODLANDS, Texas, Mar 25, 2003 /PRNewswire-FirstCall via COMTEX/ --

Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that Alan S. Nies, M.D. has been appointed as Chairman of Lexicon`s Medical Advisory Board. In his new role, Dr. Nies will assist in the development and implementation of strategies for clinical development of potential products arising from Lexicon`s drug discovery programs.

Dr. Nies brings over 40 years of clinical and pharmacological expertise to Lexicon, having most recently served as Senior Vice President, Clinical Sciences at Merck &Co., Inc. Before his ten-year career at Merck, Dr. Nies spent fifteen years as Professor of Medicine and Head of the Division of Chemical Pharmacology at the University of Colorado Health Sciences Center. During his career, Dr. Nies has served on numerous national committees and editorial boards, has received many academic and professional honors, and has authored more than 150 publications. He holds a B.S. degree from Stanford University and received his M.D. degree from Harvard Medical School.

`We are honored and pleased to have Dr. Nies join us as a key clinical advisor,`said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. `His extensive knowledge and expertise in clinical development, as a physician and pharmacologist, will be extremely valuable as our drug development programs progress towards the clinic.`

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We are using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. Our gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. We have established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize our technology and turn our discoveries into drugs. Additional information about the Company is available through Lexicon`s corporate website, www.lexicon-genetics.com .

This press release contains `forward-looking statements,`including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under `Factors Affecting Forward-Looking Statements`and `Business - Risk Factors`in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Genetics Incorporated

Chas Schultz, Director, Investor Relations and Financial Analysis of Lexicon Genetics Incorporated, [phone]

http://www.lexicon-genetics.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

03/25/2003 (16:30 ET) Lexicon Genetics Appoints Alan S. Nies, M.D. Chairman of the Medical Advisory Board - PR Newswire
03/25/2003 (11:05 ET) DEF 14A; LEXG Pxy Vote; Elect Directors; Ratify Auditor - Knobias
03/25/2003 (10:39 ET) New DEF 14A just released for LEXG - Edgar
03/19/2003 (16:15 ET) Lexicon Genetics Extends OmniBank(R) Universal Agreement With Boehringer Ingelheim Pharmaceuticals Inc. - PR Newswire
03/19/2003 (14:56 ET) VOLUME(-): LEXG Volume 60% > 20-adsv, Stock -2.11% - Knobias

JS200

[js200]

Lexicon Genetics Extends OmniBank(R) Universal Agreement With Boehringer Ingelheim Pharmaceuticals Inc.

Wednesday, March 19, 2003 16:15 ET

THE WOODLANDS, Texas, Mar 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has extended its OmniBank(R) Universal agreement with Boehringer Ingelheim Pharmaceuticals Inc. Under the terms of the agreement, Boehringer Ingelheim will continue its access to Lexicon`s OmniBank library through February 2004. Boehringer Ingelheim will also continue to have access to gene knockouts generated under Lexicon`s patented gene targeting technologies with genetic alterations directed at specific drug targets of interest, and access to drug target validation data generated by Lexicon for specified targets. Financial terms of the arrangement were not disclosed.

Lexicon Genetics Incorporated is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries. Additional information about the Company is available through Lexicon`s corporate website, www.lexicon-genetics.com .

This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Genetics Incorporated


CONTACT: Chas Schultz, Director, Investor Relations and Financial
Analysis of Lexicon Genetics Incorporated, [phone]

URL: http://www.lexicon-genetics.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Texas
INDUSTRY KEYWORD: MTC
BIO
HEA
SUBJECT CODE: LIC


STOCK SYMBOLS: [(lexg)]

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/25/2003 (16:30 ET) Lexicon Genetics Appoints Alan S. Nies, M.D. Chairman of the Medical Advisory Board - PR Newswire



03/25/2003 (11:05 ET) DEF 14A; LEXG Pxy Vote; Elect Directors; Ratify Auditor - Knobias



03/25/2003 (10:39 ET) New DEF 14A just released for LEXG - Edgar



03/19/2003 (16:15 ET) Lexicon Genetics Extends OmniBank(R) Universal Agreement With Boehringer Ingelheim Pharmaceuticals Inc. - PR Newswire



03/19/2003 (14:56 ET) VOLUME(-): LEXG Volume 60% > 20-adsv, Stock -2.11% - Knobias



03/19/2003 (08:04 ET) New SC 13D just released for LEXG - Edgar



03/18/2003 (14:20 ET) New 10-K just released for LEXG - Edgar



03/12/2003 (13:16 ET) VOLUME(-): LEXG Volume 45% > 20-adsv, Stock -1.27% - Knobias



03/11/2003 (16:22 ET) VOLUME(-): LEXG Volume 113% > 20-adsv, Stock -5.39% - Knobias



03/06/2003 (04:43 ET) Research and Markets: Lexicon Genetics, Inc.(LEXG) - Quantitative Valuation Report - M2 Communications



02/27/2003 (12:35 ET) Lexicon Genetics discovers novel target that inhibits osteoporosis - Datamonitor



02/27/2003 (07:02 ET) CONF: LEXG To Present At 2003 BIO CEO Conference @ 10:00 ET - Knobias



02/26/2003 (10:55 ET) RATING(new): Unterberg Starts LEXG @ Mkt Perform, $6 TP - Knobias



02/26/2003 (10:08 ET) RATING(=): Punk Ziegel Keeps LEXG @ Buy - Knobias



02/25/2003 (16:15 ET) Lexicon Genetics Discovers Novel Target for the Development of Treatments for Osteoporosis - PR Newswire

JS200

[js200]

http://www.knobias.com/individual/public/quote.htm?ticker=LE…

JS200

[js200]

Lexicon Genetics Licenses Patented Gene Targeting Technology to Aventis Pharmaceuticals Inc.
via COMTEX

April 22, 2003

THE WOODLANDS, Texas, Apr 22, 2003 /PRNewswire-FirstCall via COMTEX/ --

Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has licensed to Aventis Pharmaceuticals Inc. (NYSE: AVE) non-exclusive rights to its gene targeting technologies for use in Aventis`internal research programs. Financial terms of the agreement were not disclosed.

`We are very pleased to have Aventis join the prestigious group of licensees to our patented gene targeting technologies,`said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. `We believe our agreement with Aventis is further affirmation of the value of our patented gene targeting technologies as an integral resource to validate targets for drug discovery.`

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon`s corporate website, www.lexicon-genetics.com .

This press release contains `forward-looking statements,`including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under `Factors Affecting Forward-Looking Statements`and `Business -- Risk Factors`in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Genetics Incorporated

Chas Schultz, Director, Investor Relations and Financial Analysis of Lexicon Genetics Incorporated, [phone]

http://www.lexicon-genetics.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Lexicon Genetics Announces Webcast of Presentation at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
via COMTEX

April 21, 2003

THE WOODLANDS, Texas, Apr 21, 2003 /PRNewswire-FirstCall via COMTEX/ --

Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon, will speak at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference in New York at 8:30 a.m. EDT on Thursday, May 1, 2003.

A live webcast of Dr. Sands`presentation may be accessed on Lexicon`s corporate website at www.lexicon-genetics.com . An archived version of the webcast will be available on the website through May 9, 2003.

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon`s corporate website, www.lexicon-genetics.com .

This press release contains `forward-looking statements,`including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under `Factors Affecting Forward-Looking Statements`and `Business -- Risk Factors`in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Genetics Incorporated

Chas Schultz, Director, Investor Relations and Financial Analysis of Lexicon Genetics Incorporated, [phone]

http://www.lexicon-genetics.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Lexicon Genetics Appoints Philip M. Brown, M.D., J.D. Vice President Of Clinical Development
via COMTEX

April 23, 2003

THE WOODLANDS, Texas, Apr 23, 2003 /PRNewswire-FirstCall via COMTEX/ --

Lexicon Genetics Incorporated (Nasdaq: LEXG) announces that Philip M. Brown, M.D., J.D. has joined the Company as vice president of clinical development, responsible for directing clinical development of drug candidates arising from Lexicon`s drug discovery programs. Dr. Brown brings Lexicon more than a decade of experience in managing medical affairs, drug safety and clinical programs, across multiple therapeutic areas, in the pharmaceutical industry. During his career, Dr. Brown has advanced compounds from preclinical studies into clinical development and managed programs from IND through product commercialization. He has conducted over 200 phase I studies as an investigator.

`Dr. Brown`s broad medical expertise in clinical development is particularly valuable given that Lexicon`s unique approach generates clinical opportunities in cardiovascular disease, diabetes, obesity, cancer, inflammation, and neuropsychiatric disorders,`said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. `His significant experience in cardiovascular indications will also aid in accelerating some of Lexicon`s most advanced programs in atherosclerosis and metabolic disease.`

Most recently, Dr. Brown served as vice president, clinical development at Texas Biotechnology Corporation. Prior to that, he served as associate vice president, medical affairs at Pharmaceutical Research Associates, a leading international drug development organization, which now has more than 2,000 employees worldwide and is among the largest contract research organizations in the world. His other previous experience includes service as director, clinical pharmacology at Medical and Technical Research Associates and as a phase I medical associate at Pharmaco. For the last six years, Dr. Brown has also been an instructor in the graduate program in clinical investigation at Massachusetts General Hospital, Institute of Health Professions. He holds a B.A. from Hendrix College, an M.D. from the Texas Tech University Health Science Center School of Medicine and a J.D. from the University of Texas School of Law.

Recently, Lexicon announced the formation of a new Medical Advisory Board with Dr. Alan Nies appointed as chairman. Dr. Nies, formerly senior vice president, clinical sciences at Merck &Co., Inc., will provide guidance to Lexicon`s clinical development programs based on his more than 40 years experience in clinical pharmacology and drug development.

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon`s corporate website, www.lexicon-genetics.com .

This press release contains `forward-looking statements,`including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under `Factors Affecting Forward-Looking Statements`and `Business - Risk Factors`in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Genetics Incorporated

Chas Schultz, Director, Investor Relations and Financial Analysis of Lexicon Genetics Incorporated, [phone]

http://www.lexicon-genetics.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


04/23/2003 (16:31 ET) Lexicon Genetics Appoints Philip M. Brown, M.D., J.D. Vice President Of Clinical Development - PR Newswire



04/23/2003 (11:21 ET) SECTOR(HCR): Biotechs Lead Sector, Bolstered by ENMD - Knobias



04/23/2003 (06:07 ET) Lexicon Genetics licenses patented gene targeting technology to Aventis Pharmaceuticals - Datamonitor



04/22/2003 (07:30 ET) Lexicon Genetics Licenses Patented Gene Targeting Technology to Aventis Pharmaceuticals Inc. - PR Newswire



04/21/2003 (16:30 ET) Lexicon Genetics Announces Webcast of Presentation at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference - PR Newswire



04/17/2003 (16:30 ET) Lexicon Genetics to Hold First Quarter 2003 Financial Results Webcast And Conference Call - PR Newswire



04/10/2003 (12:32 ET) CONF: LEXG To Present At BioSquare 2003 Conference @ 15:30 ET - Knobias



04/10/2003 (10:44 ET) SECTOR(HCR): Biotechs Help Push Sector Lower - Knobias



04/07/2003 (14:16 ET) VOLUME(+): LEXG Volume 44% > 20-adsv, Stock +13.56% - Knobias



03/26/2003 (14:11 ET) VOLUME(-): LEXG Volume 44% > 20-adsv, Stock -4.03% - Knobias



03/25/2003 (16:30 ET) Lexicon Genetics Appoints Alan S. Nies, M.D. Chairman of the Medical Advisory Board - PR Newswire



03/25/2003 (11:05 ET) DEF 14A; LEXG Pxy Vote; Elect Directors; Ratify Auditor - Knobias



03/25/2003 (10:39 ET) New DEF 14A just released for LEXG - Edgar

JS200

[Geheimnisvoller]

Die Aktie stieg gestern sehr starkt um 8 % an der Nasdaq und heute könnte bei positiven Nachrichten der Anstieg weiter gehen.

_________________________________________________________

Lexicon Genetics to Present at the Needham & Company Second Annual Biotechnology Conference

THE WOODLANDS, Texas, Jun 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Lexicon
Genetics Incorporated (Nasdaq: LEXG) announced today that Julia P. Gregory, executive vice president and chief financial officer of Lexicon, will speak at
the Needham & Company Second Annual Biotechnology Conference in New York at 8:00 a.m. EDT on Thursday, June 5, 2003. This presentation will not be webcast.

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the
physiological functions and pharmaceutical utility of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity,
cardiovascular disease, immune disorders, neurological disease and cancer.
Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research
institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon`s corporate website,
www.lexicon-genetics.com .

This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development
of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking
statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and
Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future
events or otherwise.

http://www.lexicon-genetics.com

[Braini]

weiss jemand was ?? +26% ... das sieht doch ganz gut aus . aber ich glaub keiner ausser mir hat die aktie mehr oder ?